Eli Lilly’s rapid rise in market value in recent years has been closely tied to the surging demand for weight loss medications. The healthcare giant has emerged as a leader in the GLP-1 drug space with Mounjaro, approved for diabetes, and Zepbound, approved for weight management—two blockbuster products that are now generating billions of dollars in quarterly revenue.
What is increasingly capturing investors’ attention, however, is the potential for GLP-1 therapies to deliver benefits beyond weight loss and blood sugar control. New clinical data suggest that Lilly’s next-generation treatment could also help alleviate pain, opening the door to broader medical use and long-term growth.
Retatrutide Emerges as a Key Catalyst
One of the most closely watched drugs in Lilly’s pipeline is retatrutide, a so-called “triple agonist” that targets GIP, GLP-1, and glucagon hormones. By going beyond the mechanisms of currently approved GLP-1 drugs, retatrutide could represent a significant leap forward in obesity treatment.
Last month, Lilly released phase 3 trial results showing that patients taking a 12-milligram dose of retatrutide lost an average of 28.7% of their body weight after 68 weeks. That compares favorably with tirzepatide—the active ingredient in Mounjaro and Zepbound—which produced an average weight loss of 26.6% in a 2023 study that also included intensive lifestyle interventions.
The trial revealed another notable outcome: pain reduction. Participants included individuals with obesity and knee osteoarthritis, and more than one in eight reported being free of knee pain by the end of the study. The finding raises the possibility that retatrutide could address multiple obesity-related conditions simultaneously.
Broader Indications Could Fuel Growth
GLP-1 drugs are already in high demand for weight loss, but additional benefits—such as pain relief, treatment of sleep apnea, or reduced cardiovascular risk—could significantly expand insurance coverage and patient access.
In 2024, the U.S. Food and Drug Administration approved Zepbound for the treatment of moderate to severe obstructive sleep apnea. Retatrutide may eventually gain similar or broader indications, potentially strengthening Lilly’s competitive position in the fast-growing obesity and metabolic disease market.
The company’s financial performance underscores this momentum. In the quarter ending Sept. 30, 2025, Lilly reported a 54% jump in revenue to $17.6 billion. Mounjaro and Zepbound accounted for $10.1 billion of that total, driving the bulk of the growth. Additional approvals—including a potential oral GLP-1 treatment—could further accelerate revenue.
Valuation Remains a Point of Debate
Eli Lilly’s stock currently trades at a price-to-earnings ratio above 50, a valuation that some investors consider steep. Supporters argue the premium is justified by the company’s rapid growth, expanding pipeline, and potential for new blockbuster indications. As earnings continue to rise, the multiple could compress—unless the stock climbs further.
After gaining 39% last year and briefly reaching a trillion-dollar market capitalization, Lilly shares have pulled back somewhat. Still, many long-term investors remain bullish, viewing the company’s growing portfolio of GLP-1 therapies as a foundation for sustained expansion in the years ahead.
As the science behind obesity treatments evolves, Eli Lilly appears well positioned to benefit—not only from helping patients lose weight, but potentially from addressing pain and other chronic conditions tied to obesity.
